Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands.

Mol L, Koopman M, van Gils CW, Ottevanger PB, Punt CJ.

Acta Oncol. 2013 Jun;52(5):950-5. doi: 10.3109/0284186X.2013.777158. Epub 2013 Mar 21.

PMID:
23517248
2.

Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG).

Venderbosch S, Doornebal J, Teerenstra S, Lemmens W, Punt CJ, Koopman M.

Acta Oncol. 2012 Sep;51(7):831-9. doi: 10.3109/0284186X.2012.699193. Epub 2012 Jul 16.

PMID:
22794910
3.

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.

Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF, O'Mahony MS, Maughan TS, Parmar M, Langley RE; FOCUS2 Investigators; National Cancer Research Institute Colorectal Cancer Clinical Studies Group.

Lancet. 2011 May 21;377(9779):1749-59. doi: 10.1016/S0140-6736(11)60399-1. Epub 2011 May 11.

4.

The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer.

Shin SJ, Ahn JB, Choi HJ, Cho BC, Jeung HC, Rha SY, Chung HC, Roh JK.

Cancer Chemother Pharmacol. 2008 Jan;61(1):75-81. Epub 2007 Mar 21.

PMID:
17375304
5.

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.

Simkens LH, van Tinteren H, May A, ten Tije AJ, Creemers GJ, Loosveld OJ, de Jongh FE, Erdkamp FL, Erjavec Z, van der Torren AM, Tol J, Braun HJ, Nieboer P, van der Hoeven JJ, Haasjes JG, Jansen RL, Wals J, Cats A, Derleyn VA, Honkoop AH, Mol L, Punt CJ, Koopman M.

Lancet. 2015 May 9;385(9980):1843-52. doi: 10.1016/S0140-6736(14)62004-3. Epub 2015 Apr 7.

PMID:
25862517
6.

Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.

Moosmann N, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, Dietzfelbinger H, Oruzio D, Klein S, Zellmann K, Decker T, Schulze M, Abenhardt W, Puchtler G, Kappauf H, Mittermüller J, Haberl C, Schalhorn A, Jung A, Stintzing S, Heinemann V.

J Clin Oncol. 2011 Mar 10;29(8):1050-8. doi: 10.1200/JCO.2010.31.1936. Epub 2011 Feb 7.

PMID:
21300933
7.

Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study.

Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenburg CJ, Vreugdenhil G, Akkermans-Vogelaar JM, Punt CJ.

Ann Oncol. 2006 Oct;17(10):1523-8. Epub 2006 Jul 27.

PMID:
16873425
8.

A prospective monitoring of fatal serious adverse events (SAEs) in a Dutch Colorectal Cancer Group (DCCG) phase III trial (CAIRO) in patients with advanced colorectal cancer.

Mol L, Koopman M, Ottevanger PB, Punt CJ.

Ann Oncol. 2010 Feb;21(2):415-8. doi: 10.1093/annonc/mdp330. Epub 2009 Jul 24.

PMID:
19633046
9.

Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomised phase II study.

Price TJ, Townsend AR, Khattak A.

Ann Oncol. 2010 Oct;21(10):2121; author reply 2121-2. doi: 10.1093/annonc/mdq450. No abstract available.

PMID:
20860991
10.

The combination of capecitabine and oxaliplatin in metastatic colorectal cancer.

[No authors listed]

Clin Colorectal Cancer. 2003 Feb;2(4):205-9. Review. No abstract available.

PMID:
12620138
11.

Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.

Primrose J, Falk S, Finch-Jones M, Valle J, O'Reilly D, Siriwardena A, Hornbuckle J, Peterson M, Rees M, Iveson T, Hickish T, Butler R, Stanton L, Dixon E, Little L, Bowers M, Pugh S, Garden OJ, Cunningham D, Maughan T, Bridgewater J.

Lancet Oncol. 2014 May;15(6):601-11. doi: 10.1016/S1470-2045(14)70105-6. Epub 2014 Apr 7. Erratum in: Lancet Oncol. 2014 Jun;15(7):e253.

12.

Capecitabine combinations in the treatment of advanced colorectal cancer.

Fisher MD.

Clin Colorectal Cancer. 2001 Nov;1(3):146-8. No abstract available.

PMID:
12450426
13.

Adjuvant chemotherapy in stage III colon cancer: guideline implementation, patterns of use and outcomes in daily practice in The Netherlands.

van Gils CW, Koopman M, Mol L, Redekop WK, Uyl-de Groot CA, Punt CJ.

Acta Oncol. 2012 Jan;51(1):57-64. doi: 10.3109/0284186X.2011.633930. Epub 2011 Nov 28.

PMID:
22122695
14.

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.

Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJ, van Bochove A, Sinnige HA, Creemers GJ, Tesselaar ME, Slee PH, Werter MJ, Mol L, Dalesio O, Punt CJ.

Lancet. 2007 Jul 14;370(9582):135-42.

PMID:
17630036
15.

Strategic options on behalf of patients with metastatic colorectal cancer: mass tumor murder versus serial tumor killing.

Goldberg RM.

Onkologie. 2010;33(6):291-2. doi: 10.1159/000313683. Epub 2010 May 5. No abstract available.

16.

Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.

Kim ST, Choi YJ, Park KH, Oh SC, Seo JH, Shin SW, Kim JS, Kim YH.

Asia Pac J Clin Oncol. 2011 Mar;7(1):82-7. doi: 10.1111/j.1743-7563.2010.01363.x. Epub 2010 Dec 22.

PMID:
21332655
17.

Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.

Cartwright T, Kuefler P, Cohn A, Hyman W, Berger M, Richards D, Vukelja S, Nugent JE, Ruxer RL Jr, Boehm KA, Asmar L.

Clin Colorectal Cancer. 2008 Nov;7(6):390-7. doi: 10.3816/CCC.2008.n.052.

PMID:
19036692
18.

Safety and effectiveness of oxaliplatin-based chemotherapy regimens in adults 75 years and older with colorectal cancer.

McCleary NJ, Odejide O, Szymonifka J, Ryan D, Hezel A, Meyerhardt JA.

Clin Colorectal Cancer. 2013 Mar;12(1):62-9. doi: 10.1016/j.clcc.2012.09.001. Epub 2012 Oct 24.

19.

Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy.

Simkens LH, Koopman M, Mol L, Veldhuis GJ, Ten Bokkel Huinink D, Muller EW, Derleyn VA, Teerenstra S, Punt CJ.

Eur J Cancer. 2011 Nov;47(17):2560-7. doi: 10.1016/j.ejca.2011.06.038. Epub 2011 Jul 29.

20.

Capecitabine in combination with irinotecan or oxaliplatin in advanced colorectal cancer.

[No authors listed]

Clin Colorectal Cancer. 2003 Aug;3(2):89-91. No abstract available.

PMID:
12952563

Supplemental Content

Support Center